Literature DB >> 1334437

Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system.

R J Boado1, W M Pardridge.   

Abstract

It has been recently demonstrated that a complex of avidin, a cationic protein, and a monobiotinylated antisense oligonucleotide for the GLUT1 glucose transporter mRNA is taken up by cells in vitro and by organs in vivo via absorptive-mediated endocytosis. In the present study, a GLUT1 biotinylated oligonucleotide-avidin construct showing complete protection against serum 3'-exonuclease-mediated degradation is described. 21-mer antisense oligonucleotides complementary to nucleotides 162-182 and 161-181 of the bovine GLUT1 glucose transporter mRNA were synthesized with a 6-aminodeoxyuridine at positions 3 and 20, respectively, biotinylated with NHS- or NHS-XX-biotin to yield near 5'- or near 3'-biotinylated oligonucleotide (bio-DNA), and 5'- and 3'-end radiolabeled. Serum induced a rapid degradation of unprotected (no avidin) [5'-32P]-5'-bio-DNA (> 95% at 30 min). Avidin partially protected this construct (approximately 31% of intact 21-mer oligo remained at 1 h). Similar results were obtained with the [3'-32P]-5'-bio-DNA; however, no degradation products of varying size were observed, confirming that the degradation is mediated primarily by a 3'-exonuclease. Incubation of the [5'-32P]-3'-bio-DNA with serum showed a rapid conversion to the 20- and 19-mer forms (t1/2 approximately 13 min). Conversely, avidin totally protected this construct against the serum 3'-exonuclease. In conclusion, avidin fully protects antisense oligonucleotides biotinylated at the near 3'-terminus against serum 3'-exonuclease degradation, and this property may be useful for avidin-mediated drug delivery of oligonucleotides to tissues in vivo or to cultured cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334437     DOI: 10.1021/bc00018a010

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  6 in total

1.  Kinetics of DNA and RNA Hybridization in Serum and Serum-SDS.

Authors:  Elton Graugnard; Amber Cox; Jeunghoon Lee; Cheryl Jorcyk; Bernard Yurke; William L Hughes
Journal:  IEEE Trans Nanotechnol       Date:  2010-09-01       Impact factor: 2.570

2.  The mycobacteriophage D29 gene 65 encodes an early-expressed protein that functions as a structure-specific nuclease.

Authors:  Nabanita Giri; Priyanka Bhowmik; Bidisha Bhattacharya; Mahashweta Mitra; Sujoy K Das Gupta
Journal:  J Bacteriol       Date:  2008-11-21       Impact factor: 3.490

3.  Differential expression in glioblastoma multiforme and cerebral hemangioblastoma of cytoplasmic proteins that bind two different domains within the 3'-untranslated region of the human glucose transporter 1 (GLUT1) messenger RNA.

Authors:  H Tsukamoto; R J Boado; W M Pardridge
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.

Authors:  Sayan Mullick Chowdhury; Tzu-Yin Wang; Sunitha Bachawal; Rammohan Devulapally; Jung Woo Choe; Lotfi Abou Elkacem; Butrus Khuri Yakub; David S Wang; Lu Tian; Ramasamy Paulmurugan; Jürgen K Willmann
Journal:  J Control Release       Date:  2016-08-05       Impact factor: 9.776

5.  Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers.

Authors:  H C Chiou; M V Tangco; S M Levine; D Robertson; K Kormis; C H Wu; G Y Wu
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

6.  Development of streptavidin-based nanocomplex for siRNA delivery.

Authors:  Ravi S Shukla; Wanyi Tai; Rubi Mahato; Wei Jin; Kun Cheng
Journal:  Mol Pharm       Date:  2013-10-25       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.